Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Rheumatoid Arthritis is a chronic autoimmune condition in which the patient experiences pain, joint immobility which in some instance can also lead to disability, and thus difficulty in carrying out various activities of daily living. It is a natural consequence that patients may experience varying degrees of depressive symptoms and fatigue. Aim and Objectives: In our study, it is our objective to find out the prevalence of depression, its severity and its correlation with disease activity, pain and inflammatory markers like ESR. We also attempted to quantify the fatigue using the MAF scale by calculating the GFI (Global Fatigue Index) and its prevalence in remission vs non remission patients. Study design: The study is a cross-sectional observational study of consecutive patients with a diagnosis of RA as per EULAR 2020 criteria. The patients were interviewed using standard questionnaires MAF (multidimensional assessment of fatigue questionnaire) and PHQ9 (Patient Health Questionnaire 9). Tools used in the study: Fatigue was measured by using MAF (Multidimensional Assessment of Fatigue). Depression is measured using the PHQ9 questionnaire. Results: The population studied was found to have a prevalence of 33.5% depression. The patients’ mean age was 52.4510.53 years and disease duration 8.026.22 years. Their mean DAS28 was 2.961.1. The mean PHQ-9 score was 3.993.5., mild (26%), moderate (5.5%), moderately severe (1.5%) and severe (0.5%) degrees. Correlation of PHQ9 scores with DAS, VAS and ESR was done to see if there is a relation of depression to any of the clinical outcomes. It was found that depression had a positive correlation with disease activity score DAS 28 (coefficient of correlation 0.167, p = 0.018), VAS pain scores (coefficient = 0.361, p < 0.001) as well as ESR (coefficient = 0.217, and p = 0.002). Fatigue was evaluated using the MAF which gave the Global Fatigue Index (GFI). The mean MAF score was 8.623.33. 78% of patients had fatigue in the level (0-10), 20.5% in the (10-20) level and 1.5% in the (20-30) level. Statistical test for comparison between groups using t test was found to be significant with p value 0.034. Conclusion: Our study on both depression and fatigue once again emphasises the need for rheumatologists especially in the Indian scenario to address them in their routine clinical practice. There should be regular screening for these conditions during the patient visits similar to other risk factors screening in RA.
Rheumatoid Arthritis is a chronic autoimmune condition in which the patient experiences pain, joint immobility which in some instance can also lead to disability, and thus difficulty in carrying out various activities of daily living. It is a natural consequence that patients may experience varying degrees of depressive symptoms and fatigue. Aim and Objectives: In our study, it is our objective to find out the prevalence of depression, its severity and its correlation with disease activity, pain and inflammatory markers like ESR. We also attempted to quantify the fatigue using the MAF scale by calculating the GFI (Global Fatigue Index) and its prevalence in remission vs non remission patients. Study design: The study is a cross-sectional observational study of consecutive patients with a diagnosis of RA as per EULAR 2020 criteria. The patients were interviewed using standard questionnaires MAF (multidimensional assessment of fatigue questionnaire) and PHQ9 (Patient Health Questionnaire 9). Tools used in the study: Fatigue was measured by using MAF (Multidimensional Assessment of Fatigue). Depression is measured using the PHQ9 questionnaire. Results: The population studied was found to have a prevalence of 33.5% depression. The patients’ mean age was 52.4510.53 years and disease duration 8.026.22 years. Their mean DAS28 was 2.961.1. The mean PHQ-9 score was 3.993.5., mild (26%), moderate (5.5%), moderately severe (1.5%) and severe (0.5%) degrees. Correlation of PHQ9 scores with DAS, VAS and ESR was done to see if there is a relation of depression to any of the clinical outcomes. It was found that depression had a positive correlation with disease activity score DAS 28 (coefficient of correlation 0.167, p = 0.018), VAS pain scores (coefficient = 0.361, p < 0.001) as well as ESR (coefficient = 0.217, and p = 0.002). Fatigue was evaluated using the MAF which gave the Global Fatigue Index (GFI). The mean MAF score was 8.623.33. 78% of patients had fatigue in the level (0-10), 20.5% in the (10-20) level and 1.5% in the (20-30) level. Statistical test for comparison between groups using t test was found to be significant with p value 0.034. Conclusion: Our study on both depression and fatigue once again emphasises the need for rheumatologists especially in the Indian scenario to address them in their routine clinical practice. There should be regular screening for these conditions during the patient visits similar to other risk factors screening in RA.
Curcuma aromatica is a species of the Curcuma genus of flowering plants in the ginger family, Zingiberaceae. It is commonly known as wild turmeric, and is native to Southeast Asia, particularly India and Sri Lanka. It is traditionally used in Ayurvedic and other traditional systems for its anti-inflammatory, antioxidant, and antimicrobial properties. In the present research study, the antiproliferative activity was assessed for C.aromatica rhizome extract, rhizome essential oil and leaf oil individually. The results clearly demonstrated the efficacy of C.aromatica extracts and essential oils as a antiproliferative effect towards MDA-MB231, the Breast cancer cell line. The reduction in the cell viability of the breast cancer cell lines on treating with the extracts and essential oils individually can be attributed to Curcumin, Demethoxycurcumin and Bisdemethoxycurcumin and unique odour defining components such as cedrene, Xanthorrhizol, camphor, Germacrone, Isofuranogermacrone and 1,8-cineole. The study clearly demonstrates the antiproliferative effects of C.aromatica.
Since the beginnings of cancer research, phytochemicals have been a focal point because they were some of the first antineoplastic drugs found (e.g., leucovorin in 1950, carzinophilin in 1954, vincristine in 1963, actinomycin D in 1964, etc.). Additionally, their research is still ongoing today. It is crucial to note that natural substances are used both as adjuvants and chemotherapeutic agents in the treatment of cancer. By summarizing the three aspects of natural compounds' anticancer activity, this review offers a fresh perspective on their use in the field of oncology. Chemotherapeutic drugs because of their inherent antitumor effects, chemopreventive drugs, and sensitizers for multi-drug resistance are the first three categories. Numerous active agents are undergoing preclinical and clinical trials right now. It is crucial to draw attention to the important advancements that have been made in this field of study, with some secondary plant metabolites already in use in medicine and others being tested in human clinical trials as anticancer agents. Phytochemicals have numerous positive effects on human health and are crucial in preventing the development and spread of cancer. Through a diet high in fruits and vegetables, as well as with the aid of highly-standardized supplements containing the active compounds, one may achieve the ideal intake of natural chemopreventive agents.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.